Another study showed that the ectopic overexpression of miR-181b in TAMs could counteract the pro-tumoral effects of TAM-released CCL18 by inactivating the NF-κB pathway in BC cells in vitro [72]. This evidence concerns the gene CCL18 and breast cancer.